Findings from the GLP-1 price research

The findings

• How many sellers publish a price

  What happened when the pages of every GLP-1 seller we could find were opened and read: how many published a figure at all, and how many published one that can be compared.

  Counted over 588 sellers whose pages were opened.

• What drug the price is for

  Whether a published GLP-1 figure says which drug it prices, and how often the number sits on a page that never names one.

  Counted over 3018 published figures across 408 sellers.

• Compounded or branded

  How often a seller says, beside the figure, whether the drug is compounded or the FDA-approved product — and the one case where it almost always does.

  Counted over 3018 published figures across 408 sellers.

• What sellers do not publish

  The pharmacy, the product class, the dose schedule and the cancellation terms: four things a reader needs before buying, counted as absences with a denominator attached.

  Counted over 60 sellers whose figure states what it buys.

• The tirzepatide premium

  What the same seller charges for tirzepatide against semaglutide — and why most sellers who sell both do not publish a pair a reader can put side by side.

  Counted over 46 sellers publishing a figure for both molecules.

• What a price buys, by dose

  Whether a GLP-1 price changes with the dose, and how many sellers publish a figure that states which dose it buys at all.

  Counted over 60 of 117 sellers on this roster.

Why every one of these counts over a different set

The numbers above are not six cuts of one number, and reading them that way would get every one of them wrong. Each measurement was made on the sellers it could honestly be made on, and nothing was carried across.

588 sellers had their pages opened. 408 of them published at least one figure this reading could tie to a GLP-1 — and only those 408 can be asked what a figure named or what it disclosed. 117 publish a standing monthly rate this site can compare, and each of them has a page here. 60 of those state what dose the figure buys, and only those 60 carry a price on this site or appear in a cancellation, pharmacy or product-class census — because the other 57 were never read for any of it.

Stating a count over a set that was never read for it is the single failure this research most wanted to avoid, and it is also the failure these pages report in other people’s pages. So each finding prints its own denominator, in words, wherever the number appears.

There is one reading behind all of it, September 2026. Nothing on any of these pages describes a change over time, a trend or a price movement: only one day’s reading exists, and there is nothing to compare it against.

Where the sellers are compared

One board per buying decision, built from the 117 sellers publishing a comparable rate. Every seller read has a page under every seller we have read.

• Semaglutide providers54 listed, September 2026

  Readers who have settled on semaglutide and are choosing who to buy it from.

• Tirzepatide providers52 listed, September 2026

  Readers who have settled on tirzepatide and are choosing who to buy it from.

• Providers that publish a price before the intake59 listed, September 2026

  Readers who will not start an intake without seeing a standing rate and what it covers.

• GLP-1 providers with a published price, compared59 listed, September 2026

  Readers whose first question is the number, and who want to see what each figure actually buys before comparing them.

• GLP-1 providers for readers paying cash52 listed, September 2026

  Readers who are paying out of pocket and need the medication itself inside the published figure, not just the consult.

• GLP-1 telehealth providers60 listed, September 2026

  Readers choosing a prescriber rather than a price — who dispenses, what the plan includes, and how to leave it.

What the FDA labels say

The findings above measure what sellers published. What the drugs themselves are approved to treat, how a dose escalates and who should not take one is read from the FDA-approved prescribing information, with no company named and no paid link.

• Semaglutide vs tirzepatidereading the label

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• Dose escalation schedulesreading the label

  The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.

• Side effect ratesreading the label

  What each label reports for nausea, vomiting, diarrhoea and constipation — and the sentence every label prints above those numbers.

• Missed dose rulesreading the label

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsreading the label

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlinereading the label

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Who should not take onereading the label

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.